TrialBreast cancer research : BCR2017

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Sinead Toomey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.